Fri, Dec 26, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing

ML Capital finds Global Macro still king of alternative UCITS

Monday, July 22, 2013

Beverly Chandler, Opalesque London:

ML Capital’s Alternative UCITS Barometer’s latest report finds that investors have bullish views on US Long/Short Equity strategies. The firm writes: "US Long/Short has seen a dramatic growth in allocations with almost half of respondents planning to increase exposure levels this quarter. In contrast there are significant concerns over the economic woes continuing to plague Europe, and this has flowed through to the latest results which show a subdued level of interest in European Long/Short strategies. This may indicate an opportunistic time to launch a product that combines both themes, long US Equity whilst shorting Europe."

In contrast, investors are becoming bearish on Emerging Markets. "Investors seem to be lowering their outlook for EM equity hedge strategies, with one of the lowest results since the barometer commenced in 2011. However there still remains a respectable level of demand, with 30% of respondents planning to raise their allocations."

And Global Macro maintain its position as most popular in the field. "Global Macro-Discretionary retains its strong appeal to investors and maintains its position as the most consistently popular strategy with 48% of respondents upping their exposure levels."

The firm finds that growing confidence in the US sees a very healthy spike ......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Hong Kong-Shanghai stock link fails to live up to expectation so far[more]

    Komfie Manalo, Opalesque Asia: In a report, Reuters said that demand has been subdued with the bulk of activities coming from short-term speculative investors. Las

  2. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  3. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  4. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for

  5. CFTC Revokes Registrations of Illinois Resident Aleks A. Kins and Chicago-based AlphaMetrix, LLC[more]

    Matthias Knab, Opalesque: The U.S. Commodity Futures Trading Commission (CFTC) today announced that it has revoked the registration of Aleks A. Kins of Chicago, Illinois, as an Associated Person and the registrations of AlphaMetrix, LLC (AlphaMetrix), a Delaware limited liability company with its